For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
Posted on: Monday, 20 July 2009, 07:00 CDT
WALTHAM, Mass., July 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that most surveyed clinicians identify a need for additional therapies from the GLP-1 analogue and DPP-IV inhibitor drug classes for the treatment of type 2 diabetes. In particular, surveyed physicians identify a greater need for new GLP-1 analogues, owing to the shortcomings of the current GLP-1 analogue, Amylin/Eli Lilly's Byetta. Surveyed physicians indicate that Byetta's shortcomings include frequent injections and high levels of nausea associated with treatment. Additionally, clinicians indicate that the shortcomings of Merck's DPP-IV inhibitor Januvia include less glucose-lowering compared to metformin and a lack of long-term safety data.
The new Physician & Payer Forum report entitled A Clinician and Payer Perspective on Changing Dynamics in the Diabetes Market: Is There Room for New GLP-1 Analogues or DPP-IV Inhibitors? finds that 89 percent of surveyed endocrinologists and 77 percent of surveyed primary care physicians (PCPs) indicate there is a need for additional GLP-1 analogue therapies. The report also finds that 71 percent of endocrinologists and 74 percent of PCPs indicate there is a need for additional DPP-IV therapies.
Similarly, 75 percent of surveyed managed care organizations' (MCOs) pharmacy directors indicate that additional agents are needed within the GLP-1 analogue class, and 70 percent indicate a need for additional agents from the DPP-IV inhibitor class. Forty-five percent of MCOs indicate that a novel antidiabetic agent's glucose-lowering efficacy compared with that of existing drugs carries the most weight in their decision whether to include the novel drug in their formulary and to what tier it should be assigned.
"Surveyed clinicians indicate that although the feature of Januvia that they would most like to see improved in future DPP-IV inhibitors is its glucose-lowering efficacy, a lower cost than Januvia would be a more persuasive factor in their decision to prescribe a novel DPP-IV inhibitor," said Decision Resources Analyst Christine Helliwell, Ph.D. "Additionally, MCOs say the cost of a novel DPP-IV inhibitor relative to the cost of Januvia will strongly influence tier placement. As a result, cost could provide an effective differentiating feature for novel DPP-IV inhibitors."
A Clinician and Payer Perspective on Changing Dynamics in the Diabetes Market: Is There Room for New GLP-1 Analogues or DPP-IV Inhibitors? is based on a U.S. survey of 77 primary care physicians, 72 endocrinologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 ccomfort@dresources.com emarshall@dresources.comSOURCE Decision Resources
Source: PR Newswire
Related Articles
- Decision Resources, Inc. Named to Outsell's '10 To Watch' List
- Decision Resources' Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals' Fostamatinib Disodium
- Jeff Stewart Joins Decision Resources, Inc. as Chief Information Officer
- DecisionBase 2009 Now Available from Decision Resources
- Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI
- Novartis/Schering-Plough's Drug Will Replace AstraZeneca's Symbicort as Decision Resources' Clinical Gold Standard by 2012 for the Treatment of Asthma
- High and Super-High Potency Topical Corticosteroids Will Remain Decision Resources' Clinical Gold Standard Through 2017 for the Treatment of Atopic Dermatitis
- Decision Resources Defines a Hypothetical Parkinson's Disease Drug That Would Earn 25% Patient Share
- Top Five Healthcare Events of 2005, According to Decision Resources
- Decision Resources and PharMetrics Announce the Availability of First DecisionMETRICS Indication -- Dyslipidemia
 |
 |
User Comments (0)
RSS Feeds